Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

With sales of Novo Nordisk’s obesity blockbuster Wegovy ... in 2025 to create additional capacity “across the supply chain.” Last year, Novo said it planned to spend some 45 billion kroner ...

“In order to secure supply chain readiness, Novo Nordisk now expects to file for the first regulatory approval of CagriSema during the first quarter of 2026,” The Danish company said in its ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Novo Nordisk expects sales growth to slow this ... but in order to secure supply chain readiness, it now expects to file for the first regulatory approval of CagriSema during the first quarter ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter ... citing the need "to secure supply-chain readiness," which UBS said compares to its previous expectation of a late 2025 submission.

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Hershey's current stock decline is due to high cocoa prices, but historical trends suggest recovery once prices normalize.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Good day, and thank you for standing by. Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded.

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...